AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01681719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistance & sham WBV
Description: used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off.
Study NCT01681719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WBV & resistance sham
Description: used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min.
Study NCT04478006 — intervention group
Intervention type: GENETIC
Intervention: RNA-seq
Description: Gene expression and fusion transcripts analysis
Study NCT04478006 — intervention group
Intervention type: GENETIC
Intervention: whole exon sequencing
Description: Genetic alternation analysis
Study NCT04478006 — intervention group
Intervention type: OTHER
Intervention: Cytogenetics test
Description: Remission and relapse are monitored by cytogenetic analyses.
Study NCT00670306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Pamoate
Description: Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
Study NCT02127697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 capsules for inhalation, delivered via Concept1 once daily
Study NCT02127697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to NVA237
Description: Placebo to NVA237 delivered via Concept1 once daily
Study NCT02127697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol/ albuterol
Description: Taken as rescue medication
Study NCT02127697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: salbutamol/ albuterol
Description: Taken as rescue medication
Study NCT05637580 — intervention group
Intervention type: DRUG
Intervention: Timing of drug administration
Description: The effect of drug administration timing on tumor and lymph node responses was observed.
Study NCT02458326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
Study NCT02458326 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Training
Description: 10 minutes of heating on the treadmill with a low speed that does not cause patient effort
Study NCT03702283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penicillin Allergic Risk Stratification Best Practice Alert
Description: Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
Study NCT03097809 — intervention group
Intervention type: OTHER
Intervention: SEEG Recordings
Description: To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing
Study NCT04038021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phosphatidylethanol-based Contingency Management
Description: In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.
Study NCT04038021 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Contingent Control
Description: In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
Study NCT03839797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cadet Healthy Personal Skills
Description: 7.5 hour skills training group intervention
Study NCT03839797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Health Education
Description: Standard Health Education
Study NCT03330249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split Cisplatin
Description: 25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy.
Study NCT03330249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy.
Study NCT03330249 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.
Study NCT03330249 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.
Study NCT04919200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the single-breath helium dilution method and Whole-body plethysmography
Description: The patients with obstructive lung disease simultaneously subjected to the single-breath helium dilution method and Whole-body plethysmography tests.
Study NCT03705143 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as Usual participants will receive the treatment typically provided to patients at the MMT clinic in Wuhan, China.
Study NCT03705143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese translated LETS ACT
Description: The Chinese translated Behavioral Activation (C-BA) will be provided in Mandarin. C-BA treatment includes psychoeducation regarding the link between mood and behavior, identification of values/goals/activities across life areas, planning and tracking of daily value driven activities.
Study NCT03841201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral
Study NCT03841201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: iv infusion
Study NCT02893956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiography with postural support
Study NCT02893956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography with postural support
Study NCT02893956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiography with standard condition (usual)
Study NCT02893956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography with standard condition (usual)
Study NCT02809001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin.
Study NCT01354314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: One 100 MG capsule taken twice daily, 12 hour dosing
Study NCT01354314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Two 10 MG capsules paroxetine once daily in the evening
Study NCT01354314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine and Fluconazole
Description: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
Study NCT01354314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule in the morning, three capsules in the evening
Study NCT02806102 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study NCT02806102 — intervention group
Intervention type: DRUG
Intervention: Dual-antiplatelet therapy
Description: Dual AntiPlatelet Therapy
Study NCT02271672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XP1000 RF
Description: Treatment of adipose tissue within the fat layer with XP1000 RF.
Study NCT02271672 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham XP1000 RF
Description: Treatment of adipose tissue within the fat layer with XP1000 RF.
Study NCT00003278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00003278 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01010646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN alfa-2b XL 27 MUI + Ribavirin
Description: IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
Study NCT01010646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN alfa-2b XL 36 MUI + Ribavirin
Description: IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
Study NCT01010646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
Description: IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
Study NCT01356277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action-focused problem-solving
Description: * Adherence Support Team (patient, parent, Coach)~* standardized education on immunosuppressive medications~* identification of adherence barriers~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient
Study NCT01356277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic pillbox monitoring, dose reminders, and feedback
Description: * Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~* text message, email, or visual cue dose reminders
Study NCT01740648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
Study NCT01740648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
Study NCT01740648 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
Study NCT03895749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NEO40 Daily
Description: Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
Study NCT03895749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NEO40 Daily
Description: Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
Study NCT01167504 — intervention group
Intervention type: OTHER
Intervention: Saliva sample collection
Description: Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
Study NCT00783107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine Inhalation Solution, Once Daily
Study NCT00783107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02682043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toy car
Description: The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long.
Study NCT00722306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
Study NCT03899922 — intervention group
Intervention type: DRUG
Intervention: Drugs inducing uveitis
Description: Drugs susceptible to induce uveitis
Study NCT03233581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit + Facebook + Coaching Group
Description: Participants will use the FitBit device to track their physical activity (PA). Participants will receive and post messages and receive badges on the Facebook group. Weekly a research staff member will call them to provide brief health coaching. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide support.
Study NCT03233581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit only
Description: Participants will receive a Fitbit device only, and will not receive health coaching, join the Facebook group, or select an adult family member or friend to receive a Fitbit to provide them with support.
Study NCT02622178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
Study NCT02622178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual evoked potential
Description: Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white checkerboard pattern reversal stimulus. Electrodes are placed on the head and face to monitor Electroencephalogram (EEG) activity during testing. Output parameters from VEP system include amplitude and latency measures for each stimuli.
Study NCT00135343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanvir/ritonavir + efavirenz
Description: Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
Study NCT00135343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanvir/ritonavir + efavirenz
Description: Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
Study NCT01290770 — intervention group
Intervention type: OTHER
Intervention: blood sample
Description: blood sample at inclusion and 1 month after inclusion
Study NCT02781259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection
Description: Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
Study NCT02781259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: 10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
Study NCT02781259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging devices
Description: Near-infrared fluorescence is collected by imaging lenses and digital camera.
Study NCT04573582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: 100 mg enasidenib (CC-90007)
Study NCT02963285 — intervention group
Intervention type: OTHER
Intervention: Nasopharyngeal temperature probe
Description: Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
Study NCT02721966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody
Study NCT02721966 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody
Study NCT02721966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab and Placebo
Description: Placebo matching AIN457
Study NCT01021891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere®/Insulin
Study NCT03070964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plitidepsin
Study NCT03192553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double Gloving Procedure
Description: Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
Study NCT03192553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified Hand Hygiene Procedure
Description: Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
Study NCT03192553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One Step Procedure
Description: Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
Study NCT03192553 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CDC Procedure
Description: Participants will doff PPE using a CDC recommended procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
Study NCT02175030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copper IUD
Description: Randomization to copper/Paragard IUD for emergency contraception
Study NCT02175030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUD
Description: Randomization to Levonorgestrel/Mirena IUD for emergency contraception
Study NCT03179319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyChoices
Description: Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
Study NCT03651401 — intervention group
Intervention type: DEVICE
Intervention: Scapular muscle endurance test
Description: The SME test, developed by Edmondston et al. 17, is based on an exercise used to improve the performance of the serratus anterior and trapezius muscles. The test was carried out while the subjects were facing the wall in standing position and with their shoulders and elbows flexed to 90 degrees. While both scapulae were in neutral position, an appropriate size of stick (18-36 cm) was selected and placed between the elbows, and they were asked to hold the dynamometer (Feta 137 F0202 1 kg/10 N) between their hands.
Study NCT03651401 — intervention group
Intervention type: OTHER
Intervention: Pain intensity
Description: Pain intensity assessment was performed by questioning rest, activity, night, and measuremant pain using a visual analogue scale (VAS) on a 10 cm line with marks at both ends to define the limits of the pain experience as no pain (0) and maximum pain experienced (10), with higher scores indicating greater pain 20.
Study NCT03651401 — intervention group
Intervention type: DEVICE
Intervention: Upper Limb Functional Performance
Description: The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) protocol, which was developed by MacDermid et al. 21, was used to evaluate the functional performance of the upper extremity when performing 3 tasks.